Amendments to the Claims

1. (currently amended) A benzisothiazole-3(2H)-one compound of formula (I)



(I)

wherein;

R_1 is the group (C_4-C_{12})haloalkyl, -CF_3, (C_1-C_8)alkylcycloalkyl, or (C_3-C_8)cycloalkyl, ~~substituted benzyl, and (C_2-C_4)alkylaryl, wherein the aryl is optionally substituted and the benzyl is substituted with 1 to 3 groups independently selected from (C_1-C_{12})alkyl, (C_2-C_{12})alkenyl, (C_1-C_{12})alkoxy, and (C_1-C_{12})haloalkyl~~;

R_2 is hydrogen;

R_3, R_4, R_5, and R_6, are each independently selected from hydrogen, (C_1-C_4)alkyl, (C_2-C_4)alkenyl, -O-(C_1-C_3 alkyl), COOH, C(O)(C_1-C_3 alkyl), C(O)O(C_1-C_3 alkyl), -CF_3, and halo; or a pharmaceutically acceptable salt thereof.

2. (canceled)

3. (currently amended) A compound according to Claim 1 wherein R_1 is ~~allyl,~~ (C_3-C_4)alkylcycloalkyl, or -CF_3.

4. (canceled)

5. (canceled)

6. (previously presented) The compound of Claim 1 wherein R_5 is the group represented by chloro, bromo or CF_3.

7. (currently amended) A compound selected from the group consisting of:
3-Oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid allylamide;
~~3~~-Oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid cyclohexylamide;
~~3-Oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid 2-methyl-benzylamide;~~
~~3-Oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid 3-methyl-benzylamide;~~
~~3-Oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid 4-methyl-benzylamide;~~
~~3-Oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid 2-ethyl-6-methyl-benzylamide;~~
~~3-Oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid 2-isopropyl-6-methyl-benzylamide;~~
~~3-Oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid phenethylamide;~~
3-Oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid (4-cyclohexyl-butyl)-amide; and
6-Chloro-3-oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid cyclohexylamide~~; and~~.

8. (canceled)

9. (currently amended) A pharmaceutical formulation comprising a benzisothiazole-3(2H)-one compound of formula I according to claim 1, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent.

10-11. (canceled)

12. (currently amended) A pharmaceutical formulation containing a therapeutically effective amount of the compound of formula 1, or a pharmaceutically acceptable salt thereof, ~~wherein R_1-R_6 are defined as in claim 1~~



I

wherein:

R_1 is the group $(C_4$-$C_{12})$haloalkyl, $-CF_3$, $(C_1$-$C_8)$alkylcycloalkyl, or $(C_3$-$C_8)$cycloalkyl, substituted benzyl, and $(C_2$-$C_8)$alkylaryl, wherein the aryl is optionally substituted and the benzyl is substituted with 1 to 3 groups independently selected from $(C_1$-$C_{12})$alkyl, $(C_2$-$C_{12})$alkenyl, $(C_1$-$C_{12})$alkoxy, and $(C_1$-$C_{12})$haloalkyl;

R_2 is hydrogen;

R_3, R_4, R_5, and R_6, are each independently selected from hydrogen, $(C_1$-$C_4)$alkyl, $(C_2$-$C_4)$alkenyl, -O-$(C_1$-C_3 alkyl), COOH, C(O)$(C_1$-C_3 alkyl), C(O)O$(C_1$-C_3 alkyl), $-CF_3$, and halo;

or a pharmaceutically acceptable salt thereof;

formulated for the treatment of ~~the effect of elevated hepatic lipase activity~~ hypercholesterolemia, hyperlipidemia, or atherosclerosis.

13-15. (canceled)

16. (currently amended) The method of claim ~~10~~ 18 wherein the benzisothiazole-3(2H)-one compound is formulated with a ~~with a~~ pharmaceutically acceptable carrier or diluent.

17. (canceled)

18. (currently amended) A method of treating hypercholesterolemia, hyperlipidemia, or atherosclerosis in a mammal in need thereof comprising administering ~~using~~ a therapeutically effective amount of benzisothiazole-3(2H)-one compound of formula I, wherein R_1-R_6 are as defined in claim 1



I

or a pharmaceutical acceptable salt thereof.